• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • New Clinical Trial Exemption List for Medical Devices and IVD Reagents

New Clinical Trial Exemption List for Medical Devices and IVD Reagents

Product Technical Requirements
Monday, 25 October 2021 / Published in Medical Device, News, NMPA Registration in China

New Clinical Trial Exemption List for Medical Devices and IVD Reagents

On September 18, 2021, the NMPA (National Medical Products Administration) published the clinical trial exemption list for medical devices (No.71-2021) and IVD reagents (No.70-2021) in accordance with Order 47 and Order 48 respectively, which became effective on October 1, 2021.

Highlights

Both clinical trial exemption lists now cover 1,010 medical devices and 423 IVDs as below:

Medical DevicesIVD Reagents
Class II809374
Class III19949
Class II/III2–
Total1010423

A total of 423 products were exempted from clinical trials in this catalog including two product categories of Class III in vitro testing reagents and 11 product categories of Class II in vitro testing reagents. Comparing to the previous catalog released in December 2019, 7 newly added products include Class III products such as mumps virus IgG antibody test reagents and varicella-zoster virus IgG antibody test reagents, and Class II products such as lead test reagents.

The clinical trial exemption list for IVD reagents do not cover self-testing or new-born testing related products. The following class II IVD reagents are exempted from clinical trials:

  • Flow cytometric analysis reagents (tubes or microspheres)
  • Custom reagents (e.g. fluorescence compensation beads)

According to Order 739, clinical trials can be exempted if the safety and effectiveness of medical devices can be proven by other non-clinical evaluation studies such as existing clinical data of predicate devices in the market, clinical evaluation, etc. In August 2021, Order 47 and 48 further specified that applicants should ensure the intended use of predicate devices remains unchanged whilst no serious adverse events have occurred in the past, in order to use the existing clinical data to apply for NMPA approval.

Following the announcements on the clinical trial exemption list for medical devices and IVDs, the CMDE (Center for Medical Device Evaluation) of the NMPA released the following three technical guidelines:

  • Clinical evaluation of IVD reagents from the clinical trial exemption list
  • Clinical trial for IVD reagents
  • Determining whether to conduct clinical trials on medical devices

For the clinical evaluation of IVD reagents, the applicants can carry out the following studies:

  • Comparison study with predicate devices
  • Comparison study with measurement procedures / diagnostics accuracy standards
  • Comparison study with product information related changes

Clinical evaluation report requirements:

  • Descriptive comparative analysis
  • Comparative performance data

Cisema can customize a clinical pathway strategy for foreign manufacturers seeking the most appropriate route to NMPA approval in China covering CRO (clinical research organization) services and CER (clinical evaluation report) composition.

By Chelsey Shao and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: clinical trial, IVD reagents

What you can read next

Energy efficiency labeling requirements for electric motors
GB 16897 Test standard for brake hoses and tubing for motor vehicles, motorcycles and trailers – Implementation of new revision expected in July 2023
Next Big Step for the Introduction of Hong Kong Medical Devices to the Greater Bay Area

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP